Vista Pharmaceuticals Limited (BOM:524711)
7.52
+0.12 (1.62%)
At close: Jun 17, 2026
Vista Pharmaceuticals Revenue
Vista Pharmaceuticals had revenue of 24.18M INR in the quarter ending December 31, 2025, a decrease of -5.35%. This brings the company's revenue in the last twelve months to 86.30M, down -13.51% year-over-year. In the fiscal year ending March 31, 2025, Vista Pharmaceuticals had annual revenue of 100.75M, down -2.07%.
Revenue (ttm)
86.30M
Revenue Growth
-13.51%
P/S Ratio
5.36
Revenue / Employee
2.88M
Employees
30
Market Cap
462.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 100.75M | -2.13M | -2.07% |
| Mar 31, 2024 | 102.88M | 92.84M | 924.99% |
| Mar 31, 2023 | 10.04M | 6.09M | 154.42% |
| Mar 31, 2022 | 3.95M | -8.72M | -68.85% |
| Mar 31, 2021 | 12.66M | -214.93M | -94.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Murae Organisor | 8.59B |
| Welcure Drugs and Pharmaceuticals | 3.66B |
| Mangalam Drugs & Organics | 2.32B |
| Rajnish Wellness | 1.43B |
| JFL Life Sciences | 1.31B |
| ANG Lifesciences India | 862.13M |
| Deccan Health Care | 819.05M |
| Sandu Pharmaceuticals | 699.35M |
Vista Pharmaceuticals News
- 20 days ago - Vista Pharmaceuticals Quarterly report: Q4 2026 - Filings
- 4 months ago - Vista Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 7 months ago - Vista Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 11 months ago - Vista Pharmaceuticals Quarterly report: Q1 2026 - Filings